Photo of Mark Ball from NCI Center for Cancer Research/LinkedIn
May 25, 2024, 14:40
Dr. Mark Ball on the future of kidney cancer treatment – NCI Center for Cancer Research
NCI Center for Cancer Research shared on LinkedIn:
“CANCER CURRENTS: In a large clinical trial, treatment with pembrolizumab (Keytruda) after surgery helped people with kidney cancer live longer than those who got a placebo and standard monitoring. The findings mark the first time an adjuvant treatment for kidney cancer has improved survival.
Dr. Mark Ball, an attending surgeon and associate research physician in our Urologic Oncology Branch, weighed in on these findings and what they may mean for the future of kidney cancer treatment.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 12:13
Nov 13, 2024, 11:52
Nov 13, 2024, 11:48
Nov 13, 2024, 11:44
Nov 13, 2024, 11:39
Nov 13, 2024, 11:30
Nov 13, 2024, 11:25
Nov 13, 2024, 11:10
Nov 13, 2024, 10:59